Suppr超能文献

释放人激肽释放酶相关丝氨酸蛋白酶的治疗潜力。

Unleashing the therapeutic potential of human kallikrein-related serine proteases.

机构信息

1] Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, M5G 1X5, Canada. [2] Department of Clinical Biochemistry, University Health Network, Toronto, M5G 2C4, Canada. [3].

1] Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, M5G 0A3, Canada. [2] Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, M5S 3M2, Canada.

出版信息

Nat Rev Drug Discov. 2015 Mar;14(3):183-202. doi: 10.1038/nrd4534. Epub 2015 Feb 20.

Abstract

Tissue kallikreins are a family of fifteen secreted serine proteases encoded by the largest protease gene cluster in the human genome. In the past decade, substantial progress has been made in characterizing the natural substrates, endogenous inhibitors and in vivo functions of kallikreins, and studies have delineated important pathophysiological roles for these proteases in a variety of tissues. Thus, kallikreins are now considered attractive targets for the development of novel therapeutics for airway, cardiovascular, tooth, brain, skin and neoplastic diseases. In this Review, we discuss recent advances in our understanding of the physiological functions and pathological implications of kallikrein proteases, and highlight progress in the identification of kallikrein inhibitors, which together are bringing us closer to therapeutically targeting kallikreins in selected disease settings.

摘要

组织激肽释放酶是由人类基因组中最大的蛋白酶基因簇编码的十五种分泌性丝氨酸蛋白酶。在过去的十年中,人们在鉴定激肽释放酶的天然底物、内源性抑制剂和体内功能方面取得了重大进展,并研究阐明了这些蛋白酶在多种组织中的重要病理生理作用。因此,激肽释放酶现在被认为是为气道、心血管、牙齿、大脑、皮肤和肿瘤疾病开发新型治疗药物的有吸引力的靶标。在这篇综述中,我们讨论了人们对激肽释放酶蛋白酶的生理功能和病理影响的理解方面的最新进展,并强调了鉴定激肽释放酶抑制剂方面的进展,这些进展使我们能够在特定疾病环境中更有针对性地治疗激肽释放酶。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验